SiNtx Technologies Inc (SINT)

[boston745]

some cretin posts hallucinogenic messages on ST

Ya i dont believe "some cretin" posted the original post that the person on ST screenshot and then posted on ST. I believe its purposeful misinformation. Did they chose Eli Lilly or Lilly Eli because i often mention Amylin & Eli Lilly to compare to Sintx and Zimmer Biomet? That screenshot also came after i posted about Si3N4 being used for Cancer treatment which would be up Eli Lilly's alley. Not sure they'd use those membranes for tumor cell filtration or Solventum would? But that product is just a guess as to what is being developed with a partner for cancer treatment.

The parallels between Sintx and Amylin are uncanny. Both being co-founded by individuals connected to major players in their fields with personnel from those large players being on their respective boards most of their existence. While i thought Mr. Icahn came in and ruined the eventual acquisition of Amylin by Eli Lilly, it actually appears as though Eli Lilly & Bristol Myer did a trade behind the scenes as both companies acquired the companies each other were partnered with; Eli acquired ImClone in 2008 (partnered with Bristol in 2002) and Bristol acquiring Amylin in 2012 (partnered with Eli in 2002). Still the evidence suggests Eli always intended to see Amylin acquired. The whole Icahn ordeal appearing to be a big show for those not in the know.


In 1996 Amylin had an operating deficit of $155m. Like Sintx, Amylin ran into issues/experienced setbacks in R&D. Like Sintx, Amylin lost all revenue during its R&D phase but that is because J&J pulled out of the partnership while Sintx sold off its old assets to become Sintx. Just like Amylin, Sintx stock has tanked. Difference being that Amylin stock began recovering before a new collaboration was formed and obviously went up from there.

The parallels do not stop there however and just so happen to go back to the beginning of the companies.

Amylin was co-founded by Mr. Howard Greene in 1987, who just so happened to sell a company to Eli Lilly in 1986.
Sintx was co-founded by Dr Aaron Hofmann in 1996 who was a surgeon designer for Centerpulse.
Dr. Max Link was Chairman & CEO of Centerpulse from March 2002 to October 2003 when it was sold to Zimmer Holdings, Inc. That same month Dr Link became Chairman of Sintx's board.

In 1994, two former Eli Lilly executives joined the board of Amylin, the same year it went public.
2012, Dr Sonny Bal a surgeon designer for Zimmer Holdings, Inc and joined Sintx board of directors while it was still a private entity.

In 1998, one of those two former Eli Lilly executives became Chairman and CEO of Amylin.
August 2014, after Dr Link stepped down for health reasons and after Sintx went public as Amedica, February 2014, Dr Sonny Bal stepped into the role as Chairman. Then in October, Dr Bal took over as CEO as well.

It is interesting that both Amylin and Sintx were founded with ties to companies that maintained a watchful eye on development throughout their journey. For Amylin, Eli Lilly was there from the founding until 2011.

Both Joseph Cook and Dr. Bal steered their respective companies through some challenges. However by the looks of it Cook did more to put thing in order in a relative short time. Cook cut costs, just like Dr Bal and he forged ahead with development for 4 years before hitting a breakthrough. In that same time Dr Bal rebranded Amedica as Sintx, sold off old IP, and diversified Sintx direction. However, because Mr. Cook signed a development deal in 2002 with his former company Eli Lilly, Amylin had risen from the dead. This is something i still wait for Dr. Bal to do, sign some sort of agreement with the company he was a surgeon designer and scientist for since 2002. While Dr. Bal has used Zimmer Biomet IP in developing Sintx products and Zimmer Biomet hired a coatings expert in 2018, neither company has officially announced any sort of collaboration. Still you can see the similarities in both Amylin and Sintx.

Mr. Cook stepped down from his role as CEO in 2003 allowing another former Eli Lilly executive to takeover but he retained his role as Chairman until 2009. If you do the research, it was suggested that Eli Lilly intended to acquire Amylin at some point and that Amylin management was not in a hurry to sell because they could secure more money for investors, including themselves, if they waited. However it was in 2008 i believe, that Mr Carl Icahn stepped into the picture and dismantled everything. He removed Cook in 2009. Tried to get Eli Lilly to acquire Amylin, but as it turns out, Eli Lillly may not have needed Amylin like it once did. It seems it put focus on other drugs. Icahn eventually sold Amylin to Bristol Myers in 2012.

ImClone in hand and a potential approval of blockbuster prasugrel coming, Lilly needs Amylin much less than it used to.

2002 Bristol Myer signs a collab with ImClone but runs into problems. 2008, Bristol puts in an offer for ImClone but Eli acquired it with a higher offer with Icahn owning shares in ImClone. Then after selling ImClone to Eli, Icahn takes Amylin from Eli and sells it to Bristol. Looks like some backroom deal was made and the companies traded drugs somehow.

========================================

Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application

examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.

https://www.mdpi.com/2571-6131/4/2/16/htm

========================================

List of Markets Sintx can participate in and products in development:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174489883

========================================

Sintx valuation should be greater than $230m based on comparable company:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174491281

========================================

Silicon Nitride = Next Gen Hip Implant Material

Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies

Im guessing the authors meant Sintx Technologies. Amedica being the companies former name before the name was sold to CTL.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422432/

========================================

Electromagnetic fields, metal implant corrosion, and dis-ease it causes


https://i.imgur.com/nLg7SXT.jpg

Cancer-Causing Effects of Orthopaedic Metal Implants in Total Hip Arthroplasty
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11011042/

Oral Cancer around Dental Implants: Are the Clinical Manifestations and the Oncogenic Mechanisms Unique?
https://www.intechopen.com/chapters/79298

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172932779